1	Perceptions and priorities for the development of multiplex rapid diagnostic tests for
2	acute non-malarial fever in rural South and Southeast Asia:
3	an international modified e-Delphi survey
4	
5	Short title: Prioritization of analytes for acute non-malarial fever multiplex rapid diagnostic tests
6	
7	Authors: Rusheng Chew ^{1,2,3} ; Salisa Lohavittayavikant ¹ ; Matthew Mayer ⁴ ; Nicholas PJ Day ^{1,2} ; Yoel
8	Lubell ^{1,2}
9	
10	Affiliations: ¹ Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand; ² Centre for
11	Tropical Medicine and Global Health, University of Oxford, Oxford, UK; ³ Faculty of Medicine,
12	University of Queensland, Brisbane, Australia; ⁴ Freelance information technology consultant
13	
14	Corresponding author details: Dr Rusheng Chew, Mahidol Oxford Tropical Medicine Research Unit,
15	3rd floor 60th Anniversary Chalermprakiat Building, 420/6 Ratchawithi Road, Ratchathewi, Bangkok
16	10400, Thailand. Email: chris@tropmedres.ac Phone: +66 2 203 6333
17	
18	Author contributions: RC – conceptualization, methodology, investigation, formal analysis,
19	visualization, writing – original draft; SL – software, data curation, writing – review and editing; MM
20	– software, writing – review and editing; NPJD – supervision, funding acquisition, writing – review
21	and editing; YL – conceptualization, methodology, supervision, funding acquisition, writing – review
22	and editing
23	
24	Key words: Fever; Delphi survey; rapid diagnostic test; Southeast Asia; South Asia
25	
26	Word to me print reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 ABSTRACT

28

29 Background. Fever is a common presenting symptom in low- and middle-income countries (LMICs). 30 It was previously assumed that malaria was the cause in such patients, but its incidence has declined rapidly. The urgent need to develop point-of-care tests for the most important causes of non-31 32 malarial acute febrile illness is hampered by the lack of robust epidemiological data. We sought to obtain expert consensus on analytes which should be prioritized for inclusion in fingerprick blood-33 34 based multiplex lateral flow rapid diagnostic tests (LF-RDTs) targeted towards four categories of 35 patients with acute non-malarial fever in South and Southeast Asian LMICs, stratified by age 36 (paediatric vs. adult) and care setting (primary vs. secondary care). 37 Methodology/Principal Findings. We conducted a two-round modified e-Delphi survey. A total of 84 38 panellists were invited, consisting of seven each from 12 countries, divided into three regional 39 panels (Mainland Southeast Asia, Maritime Southeast Asia, and South Asia). Panellists were asked to 40 rank their top seven analytes for inclusion in LF-RDTs to be used in each patient category, justify 41 their choices, and indicate whether such LF-RDTs should be incorporated into algorithm-based 42 clinical decision support tools. Thirty-six panellists (43%) participated in the first round and 44 (52%) 43 in the second. There was consensus that such LF-RDTs should be incorporated into clinical decision 44 support tools. At a minimum, these LF-RDTs should be able to diagnose dengue and enteric fever in 45 all patient categories. There was a clear preference to develop LF-RDTs for pathogens not readily 46 detected by existing technologies, and for direct diagnosis through antigen detection. Pathogen 47 biomarkers were prioritized over host inflammatory biomarkers, with CRP being the only one ranked 48 consistently highly. 49 **Conclusions/Significance.** Our results provide guidance on prioritizing analytes for inclusion in 50 context-specific multiplex LF-RDTs and similar platforms for non-malarial acute febrile illness, for

51 which there is an urgent unmet need.

52 AUTHOR SUMMARY

53

54 In rural South and Southeast Asia, most acute febrile illness was previously attributable to malaria 55 but the incidence of malaria is declining. To aid diagnosis and prognosis in patients presenting with 56 the common symptom of acute fever with no localising features but in whom malaria has been 57 excluded, there is an urgent need to develop minimally-invasive rapid diagnostic tests (RDTs) which 58 can test for multiple pathogen and host biomarkers. Obtaining expert consensus opinions on what 59 biomarkers these tests should detect will contribute greatly to their development, but there is a 60 paucity of robust epidemiological data on the diverse non-malarial causes of acute fever. We 61 determined the biomarkers which should be included in region-specific fingerprick blood-based RDTs 62 tailored to four patient categories differentiated by age and level of care, in the form of seven-item 63 lists ranked in decreasing order of priority. To provide context for these rank lists, we ascertained 64 the principal factors influencing expert priority-setting and explored perceptions of the clinical utility 65 of such RDTs. Our results provide essential region-specific guidance to aid development of RDTs for 66 acute non-malarial fever, for which there was strong consensus for their inclusion in clinical decision-67 making tools for low- and semi-skilled healthcare staff.

68 INTRODUCTION

69

70 Fever is a common but non-specific sign of sepsis.[1] In regions with high burdens of infectious 71 diseases such as South and Southeast Asia, many patients present acutely with fever but without 72 localising signs and symptoms. It was previously assumed that malaria was the cause in most 73 patients presenting with such fevers, but the roll-out of highly accurate malaria rapid diagnostic tests 74 along with the success of public health efforts to eradicate malaria has resulted in a large decline in 75 malaria incidence.[2, 3] Febrile illnesses, however, are still a common cause for seeking medical care 76 in rural communities and, while early intervention is crucial in the management of sepsis, obtaining 77 clinical and/or microbiological diagnoses is difficult in these resource-poor settings. 78 79 Fingerprick blood-based rapid diagnostic tests for several other infectious diseases based on lateral 80 flow technology e.g., HIV and Ebola virus disease, have been developed and rolled out in both high-81 and low-resource settings. [4, 5] These are generally immunoassays based on the detection of 82 microbial antigens and/or antibodies against the causative pathogens, although nucleic acid-based 83 assays have more recently been developed.[6] Similar to these pathogen biomarker assays, tests for 84 several host inflammatory biomarkers of potential diagnostic and/or prognostic significance are also 85 available.[7] The test kits comprise of a recognition layer containing the detection sites, combined 86 with a porous membrane which draws the fluid to be tested past the detection sites by capillary 87 action.[8] They are low-cost, simple to operate, require no specialised equipment, and can be used 88 at the point of care, returning results in 30 minutes or less, thus making them ideal for use in low-89 resource settings.[9, 10]

90

91 These features, along with the endemicity of myriad infectious diseases in the region, poorly trained
92 health workforce, and lack of diagnostic microbiology capability create a pressing need for multiplex
93 lateral flow rapid diagnostic test kits (LF-RDTs) for multiple infections to guide patient management

94 with the minimum amount of test substrate. The use of multiple single-disease LF-RDTs is unlikely to 95 be cost-effective or logistically feasible, and is sub-optimal for patient comfort. However, 96 ascertainment of the most important infective aetiologies of fever to aid the development of 97 relevant multiplex LF-RDTs and other diagnostic tools in South and Southeast Asia is hampered by 98 the paucity of reliable epidemiological data covering not just incidence, but also disease burden in 99 terms of morbidity and mortality.[11] There is, thus, a high degree of uncertainty in prioritization of 100 pathogens for inclusion in such tests; furthermore, what little published evidence there is comes 101 mainly from cities, rather than rural areas where most of the population live.[12] In addition, there is 102 growing interest in augmenting pathogen-based diagnostics by assaying host biomarkers of 103 inflammation in parallel, in particular those which can assist in the differentiation viral from non-viral 104 infections, thus improving antimicrobial stewardship, [13] or predict or indicate severe disease, thus 105 improving the identification of patients who require escalation of care.[14] 106 107 Given the poor understanding of the epidemiology of febrile illness in South and Southeast Asia, we 108 conducted a modified e-Delphi survey to obtain expert consensus on pathogen-specific and host 109 inflammatory biomarker analytes which should be prioritized for inclusion in multiplex LF-RDTs with 110 fingerprick blood as the test substrate, for use in acutely febrile rural residents of South and 111 Southeast Asian low- and middle-income countries (LMICs) who test negative for malaria and in 112 whom the source of infection is unclear. We also aimed to explore the reasoning and contextual 113 background underlying the selection of these analytes.

114 METHODS

115

116	The survey was conducted over two rounds from 20 April to 20 June 2022, and delivered via
117	anonymous web-based questionnaires administered through a bespoke platform. Reminder emails
118	were sent weekly to optimize participation rates. Prior to launch, two experts who would have
119	otherwise been invited as panellists were asked to review the survey to ensure face validity,
120	readability, and usability.
121	
122	Given the likely spatio-temporal heterogeneity in disease profiles, three regional panels were
123	assembled: South Asia (India, Bangladesh, Pakistan, and Nepal), Mainland Southeast Asia (Thailand,
124	Laos, Myanmar, Peninsular Malaysia, and Cambodia), and Maritime Southeast Asia (Indonesia,
125	Timor-Leste, and the Philippines). Countries were selected to ensure adequate geographical
126	representation, with at least one small country (in terms of relative population size) included per
127	panel.
128	
128 129	Participant selection
	Participant selection
129	Participant selection A total of 84 experts (seven from each country) were invited to participate in each round. Potential
129 130	
129 130 131	A total of 84 experts (seven from each country) were invited to participate in each round. Potential
129 130 131 132	A total of 84 experts (seven from each country) were invited to participate in each round. Potential panelists were shortlisted through searches of national infectious diseases and/or tropical medicine
129 130 131 132 133	A total of 84 experts (seven from each country) were invited to participate in each round. Potential panelists were shortlisted through searches of national infectious diseases and/or tropical medicine specialty society office-bearers; leaders of health-related non-governmental organizations and
129 130 131 132 133 134	A total of 84 experts (seven from each country) were invited to participate in each round. Potential panelists were shortlisted through searches of national infectious diseases and/or tropical medicine specialty society office-bearers; leaders of health-related non-governmental organizations and governmental bodies; researchers from university departments or faculties; and recommendations
129 130 131 132 133 134 135	A total of 84 experts (seven from each country) were invited to participate in each round. Potential panelists were shortlisted through searches of national infectious diseases and/or tropical medicine specialty society office-bearers; leaders of health-related non-governmental organizations and governmental bodies; researchers from university departments or faculties; and recommendations of experts already selected. The final list was constructed based on work experience, expertise and
129 130 131 132 133 134 135 136	A total of 84 experts (seven from each country) were invited to participate in each round. Potential panelists were shortlisted through searches of national infectious diseases and/or tropical medicine specialty society office-bearers; leaders of health-related non-governmental organizations and governmental bodies; researchers from university departments or faculties; and recommendations of experts already selected. The final list was constructed based on work experience, expertise and reputation, involvement in health policymaking, and publication record. To balance perspectives, at

140

141 First round

142

143	In the first round, participants were provided with four scenarios in which they were required to
144	rank seven analytes from a list of pathogen-specific and host inflammatory biomarkers for
145	hypothetical LF-RDTs for acute (≤14 days duration) non-malarial fever of unclear source to be
146	developed for year-round use in each region. The four scenarios corresponded to four patient
147	categories stratified by age and level of care i.e., children (age >28 days and <15 years) and adults
148	(age ≥15 years) seeking healthcare in the community from village health workers or primary health
149	facilities, and being admitted to rural hospitals with limited diagnostic capacity, respectively.
150	Neonates were not included because neonatal febrile illness generally requires assessment and
151	thorough investigation in secondary or higher-level care.[15]
152	
153	Pathogen biomarker options were based on a recent systematic review of published aetiological
154	studies and case reports on non-malarial fever in South and Southeast Asia,[16] while host
155	inflammatory biomarker options were selected on the basis of biological plausibility and a non-
156	systematic survey of the literature.[17, 18] Participants were able to recommend non-listed analytes
157	as well as refine the provided choices, such as specifying a particular type of antigen, and were asked
158	to explain the reasoning behind their decisions for each scenario. If a host inflammatory biomarker
159	was selected, participants were required to state its perceived utility from the following options:
160	'differentiation of viral and non-viral fever', 'as a marker of severity', 'both of these reasons', or
161	'other'.
162	
163	To assess the perceived value of LF-RDTs in these patient categories, participants were asked
164	whether they would find such a test with a minimum sensitivity of 75% and minimum specificity of

165 90% across all targets helpful to guide clinical decision-making, and whether they would recommend

166 its inclusion in electronic algorithm-based clinical decision support tools for use in their countries. 167 Finally, to provide further context, participants were asked to rank what they perceived to be the 168 five commonest causes of acute febrile illness in their regions in terms of annual incidence. 169 Consensus was achieved if \geq 80% of the participants for each region agreed on a particular response. 170 Questions for which consensus was achieved in the first round were not repeated. 171 At the conclusion of the first round, participants were invited to provide free-text feedback on the 172 173 survey structure and questions. Free-text suggestions for improvement were analysed thematically 174 and used to inform the subsequent iteration of the questionnaire. Changes were made based on the 175 number of times an issue was raised, the practicality of the suggested change, and its relevance to 176 the context of the survey. 177 178 Second round 179 180 All panellists were re-invited to participate in the second round run two weeks after the end of the 181 first, unless they explicitly declined to participate in the first round. The latter (n=10) were replaced 182 in the second round, while maintaining the gender and clinician balance described previously. 183 184 In this round, only options that had been selected in the first round for each scenario were included. 185 First-round respondents who participated in the second round were shown their previous answers 186 to each question. To assist participants in reaching consensus, the frequencies of every analyte 187 selected in each rank position, along with their sum of weighted scores, were shown graphically. An 188 analyte ranked first was assigned a weighted score seven times more than if it was ranked last. 189 Similarly, for the question on the commonest causes of acute febrile illness, an aetiology ranked first 190 was assigned a weighted score five times more than if it was ranked last. The factors influencing

- 191 participant reasoning for their rankings from the first round were analysed thematically and
- 192 presented as discrete options in this round.

193

- 194 In the event that consensus for each rank position was unable to be reached by the end of the
- second round, agreement was quantified by constructing rank lists of the seven highest-scoring
- analytes for each scenario and of the five highest-scoring aetiologies of febrile illness were

197 constructed.

- 198
- 199 Statistical analyses were performed using Microsoft Excel (Microsoft, Washington, USA).

200 **RESULTS**

201

202	Thirty-six experts participated in the first round and 44 in the second round, giving overall response
203	rates of 43% and 52%, respectively. Thirty-four of the 36 (94%) first round-respondents also
204	participated in the second round; in this round, regional panel response rates were between 38%
205	and 66%. Participant demographic and professional background details by region for both rounds
206	are shown in Table 1.
207	
208	First round
209	
210	In all panels, there was consensus that such LF-RDTs would help clinical decision-making in all target
211	patient populations, and for the incorporation of these tests into electronic algorithm-based clinical
212	decision support tools for use in their respective countries.
213	
214	The reasons given by participants for the ordering of their rank lists were distilled into the following
215	statements, which were used as response options in the second round: 'disease prevalence and/or
216	incidence in this age group and care setting', 'potential disease severity and need (or otherwise) for
217	antimicrobial therapy or referral', 'host biomarkers are more useful than aetiological diagnosis in this
218	age group and care setting', 'aetiological diagnosis is more useful than host biomarkers in this age
219	group and care setting', 'pathogens for which there are available RDTs should be prioritised',
220	'pathogens for which there are no available RDTs should be prioritised', and 'other'.
221	
222	Second round

223

224	The consensus threshold was not reached for any position in any rank list. Therefore, for each region
225	the seven highest-scoring analytes for each scenario and the five highest-scoring aetiologies of acute
226	febrile illness, based on the sums of their weighted scores, were used to construct the rank lists.
227	
228	Across all regions, in both primary and secondary care settings and for both paediatric and adult
229	patients dengue NS1 and typhoidal Salmonella antigens occupied the top two rank positions (Figures
230	1–3). This is in keeping with the perception that dengue and enteric fevers are among the top five
231	causes of acute febrile illness in all regions (Figure 4), and with the unsurprising finding that
232	perceived disease incidence and/or prevalence was a primary factor in analyte selection (Figure 5).
233	Also in line with current evidence on the near-elimination of malaria, the disease was thought to be
234	a leading cause of acute febrile illness only in Maritime Southeast Asia (Figure 4).
235	
236	In mainland Southeast Asia, Burkholderia pseudomallei, Orientia tsutsugamushi, and Rickettsia
237	antigens also featured in the rank lists for each scenario, as did Leptospira antigen in maritime
238	Southeast Asia (Figures 1–3). While only <i>Rickettsia</i> was listed among the top five aetiologies of acute
239	febrile illness in mainland Southeast Asia (Figure 4), the inclusion of these organisms is reflective of
240	another major factor influencing analyte selection i.e., the prioritisation of pathogens which require
241	specific directed antimicrobial therapy and have the potential to cause severe disease (Figure 5).
242	
243	There was a clear preference for antigen-based pathogen biomarkers over serological analytes,
244	including for pathogens like typhoidal Salmonella where such capillary blood-based rapid tests are
245	not yet available (Figures 1–3). This finding also reflects the view of the majority of respondents that
246	pathogens for which there are no readily available RDTs should be prioritised for inclusion when
247	developing multiplex LF-RDTs (Figure 5).

249 The only host inflammatory biomarker which featured prominently in this survey was C-reactive 250 protein (CRP). CRP was included in all rank lists except those for adult secondary care in Mainland 251 and Maritime Southeast Asia (Figures 1–3). However, it was most frequently found in the bottom 252 half of rank lists, indicative of the majority opinion that host biomarkers are less useful than 253 microbiological diagnosis (Figure 5). 254 255 Furthermore, while twenty-eight (64%) respondents across all panels ranked CRP in one or more 256 scenarios, there was little agreement on use case. Eight (29%) believed it was a good discriminator 257 between viral and non-viral infections in all scenarios in which CRP featured in their rank lists, while 258 two (7%) believed it to be a good marker of disease severity. A further eight (29%) thought CRP was 259 able to fulfil both use cases, while 10 (36%) were of the opinion that use case varies depending on 260 patient age and care setting. 261 262 For the scenario-based questions, the top-ranked three analytes in each rank list were unchanged 263 between the first and second rounds although their individual positions varied slightly, except for 264 the Maritime Southeast Asia and South Asia adult secondary care rank lists where the top-ranked 265 two analytes were constant between rounds. The top-ranked analyte in all rank lists in the first

round was either dengue NS1 antigen or typhoidal *Salmonella* antigen, demonstrating a degree of convergence at the end of the survey as both these analytes occupied the top two positions in all lists in the second round. The top three perceived aetiologies of acute febrile illness in all regions

269 were also unchanged between rounds.

Region		Charac	teristic	Round 1 (n, %)	Round 2 (n, %)
			Thailand	2 (11)	5 (22)
			Laos	5 (26)	5 (22)
	Cou	intry	Cambodia	3 (16)	3 (13)
			Myanmar	4 (21)	4 (17)
			Peninsular Malaysia	5 (26)	6 (26)
	Gender		Male	15 (79)	17 (74)
Mainland			Female	4 (21)	6 (26)
Southeast			Clinical infectious diseases	10 (52)	10 (43)
Asia [n = 19 (54%) and		Clinical	Clinical infectious diseases and medical microbiology	4 (21)	5 (22)
23 (66%) in rounds 1	Professional		Other	1 (5)	2 (9)
and 2,	role		Medical microbiology	3 (16)	3 (13)
respectively]		Non-clinical	Epidemiology	2 (11)	1 (4)
			Microbiology	1 (5)	2 (9)
			0 to 5	0 (0)	1 (4)
			>5 to 10	1 (5)	1 (4)
	Years of e	experience	>10 to 15	4 (21)	5 (22)
			>15 to 20	3 (16)	3 (13)
			>20	11 (58)	13 (57)
			Indonesia	2 (33)	3 (38)
	Coι	intry	Philippines	1 (17)	1 (13)
			Timor-Leste	3 (50)	4 (50)
Maritime Southeast			Male	1 (17)	3 (38)
Asia [n = 6	Gei	nder	Female	5 (83)	5 (62)
(29%) and 8			Clinical infectious diseases	5 (83)	5 (63)
(38%) in rounds 1	Professional role	Clinical	Clinical infectious diseases and medical microbiology	0 (0)	1 (13)
and 2,			Other	1 (17)	2 (25)
respectively]			>5 to 10	2 (33)	3 (38)
	Years of e	experience	>10 to 15	3 (50)	2 (25)
			>20	1 (17)	3 (38)
	_		India	2 (18)	2 (15)
			Nepal	3 (27)	4 (31)
	Cou	intry	Pakistan	4 (36)	5 (38)
			Bangladesh	2 (18)	2 (15)
	-		Male	7 (64)	7 (54)
South Asia	Gei	nder	Female	4 (36)	6 (46)
[n = 11	Professional role	Clinical Non-clinical	Clinical infectious diseases	7 (64)	7 (54)
(39%) and 13 (46%) in rounds 1			Clinical infectious diseases and medical microbiology	1 (9)	1 (8)
and 2,			Other	1 (9)	1 (8)
respectively]			Medical microbiology	1 (9)	2 (15)
. ,,			Public health	0 (0)	1 (8)
			Other	1 (9)	1 (8)
	Years of experience		>10 to 15	0 (0)	3 (23)
			>15 to 20	4 (36)	3 (23)
			>20	7 (64)	7 (54)

Table 1. Regional panel participant demographic and professional background details.

272 DISCUSSION

273

274 The results of this survey indicate that multiplex LF-RDTs for non-malarial acute febrile illness to be 275 developed for use in South and Southeast Asia should be able to diagnose dengue and enteric fever 276 in all age groups and care settings. There was also a clear desire for the development of LF-RDTs for 277 pathogens not readily detected by existing technologies, and for these new tests to diagnose 278 diseases directly through antigen detection. Pathogen biomarkers were prioritized over host 279 biomarkers, for which the only contender for inclusion was CRP although there was little agreement 280 on use case. The majority of the other pathogen biomarkers selected reflect the almost equal 281 consideration given to clinical and epidemiological burdens of disease. Importantly, there was strong 282 and early consensus that such LF-RDTs would aid clinical decision-making and that they should be 283 incorporated into algorithm-based clinical decision support tools.

284

285 Our study has several strengths. Firstly, the modified Delphi method is well-suited to address the 286 research question, given the challenges in collecting comprehensive epidemiological data before 287 commencing work on LF-RDT development. The Delphi survey is a well-established technique 288 facilitating consensus decision-making and avoiding domination by individual experts, as it is 289 anonymous, systematic, iterative, and inclusive of a range of opinions. [19, 20] Secondly, we adhered 290 to best practice by pre-specifying the consensus definition, panellist selection criteria, and closing 291 criterion, and by providing timely, well-structured controlled feedback. [21, 22] In addition, we 292 ensured generalizability through assembling appropriately-sized panels of suitably qualified 293 members from diverse backgrounds and countries, [21] and by taking steps to ensure that the 294 response rate for each panel exceeded the approximately 30% response rate typical of online 295 surveys. [23] Thirdly, the participant retention rate between the two rounds was high. However, by 296 re-inviting panellists who did not participate in the first round, we avoided the possibility of false 297 consensus and ensured optimal representation of perspectives. [24] Fourthly, although response

stability was not a closing criterion, the consistency of the top-ranked two to three responses to
each question between rounds is indicative of the reliability of our results.[22, 25]

300

The principal weakness of our study is that consensus, as per the prespecified definition, was not reached with regard to analyte rankings. However, we had anticipated this possibility and, thus, prespecified an alternative method of analyte prioritisation based on sums of weighted scores. Secondly, for pragmatic reasons we only surveyed experts from 12 out of the 15 LMICs in South and Southeast Asia. However, because panellist selection was weighted towards large countries both in terms of area and population, our results are still likely to be of considerable benefit in informing the development of LF-RDTs to be used in these regions.

308

309 Our results complement and extend previous work by Osborn et al. which, to our knowledge, is the 310 only other study which has attempted to address this important question. They conducted a global 311 prioritization exercise for a cartridge-based diagnostic test for pathogens causing severe febrile 312 illness without a known source in patients presenting to secondary care.[26] Unlike their study, ours 313 concentrated on acute non-malarial fever in both primary and secondary care settings with patients 314 stratified by age, included host inflammatory biomarkers as options, and adopted a more granular 315 regional focus. Both studies had typhoidal *Salmonella* as a top priority pathogen in addition to 316 leptospirosis and rickettsioses, but we also recognized dengue and melioidosis as other major 317 priorities given our emphasis on rural South and Southeast Asia. Additionally, for each pathogen we 318 explored what participants deemed the ideal analyte, as well as the motivations and reasoning 319 behind their choices. Our findings, therefore, add further layers of context which are essential to 320 ensuring acceptability and applicability, two key challenges facing the development and 321 implementation of any such LF-POCTs developed for use in these regions.[27]

322

323	The obvious implication of this study is its value in informing analyte selection for multiplex LF-RDT
324	development. In general, while current LF-RDT technologies do not yet permit the detection of more
325	than 2-3 analytes from fingerprick blood, new diagnostic methods which allow detection of more
326	analytes without an increase in sample volume are in development. Examples of these are CRISPR-,
327	aptamer-, and SOMAmer-based multiplex assays which will also facilitate adaptation of the analyte
328	panels, making them more context-specific.[28, 29] The seven-item rank lists constructed will, thus,
329	serve as a reference point as to which analytes to prioritise for inclusion in expanded panels in line
330	with the target product profile for multiplex multi-analyte diagnostic platforms for acute febrile
331	illness published by the World Health Organization.[30] Finally, we have also identified two key
332	questions for future research. The first is the validation of setting-specific CRP use cases and the
333	determination of cut-off levels to ensure sufficient sensitivity and specificity for each use case. The
334	second is the development and validation of antigen-based LF-RDTs for typhoidal Salmonella, since
335	no such tests have been developed despite the interest demonstrated by our study.
336	
336 337	ACKNOWLEDGEMENTS
	ACKNOWLEDGEMENTS
337	ACKNOWLEDGEMENTS We thank the experts who participated in this study, a list of whom can be found in Supplemental
337 338	
337 338 339	We thank the experts who participated in this study, a list of whom can be found in Supplemental
337 338 339 340	We thank the experts who participated in this study, a list of whom can be found in Supplemental
337 338 339 340 341	We thank the experts who participated in this study, a list of whom can be found in Supplemental Appendix 1.
 337 338 339 340 341 342 	We thank the experts who participated in this study, a list of whom can be found in Supplemental Appendix 1.
 337 338 339 340 341 342 343 	We thank the experts who participated in this study, a list of whom can be found in Supplemental Appendix 1.
 337 338 339 340 341 342 343 344 	We thank the experts who participated in this study, a list of whom can be found in Supplemental Appendix 1.
 337 338 339 340 341 342 343 344 345 	We thank the experts who participated in this study, a list of whom can be found in Supplemental Appendix 1. COMPETING INTERESTS The authors declare no competing interests.

349	
350	FUNDING
351	
352	This research was funded in whole, or in part, by the Wellcome Trust [215604/Z/19/Z]. RC was also
353	funded by the UK Government through a Commonwealth Scholarship, and the Royal Australasian
354	College of Physicians through the Bushell Travelling Fellowship in Medicine or the Allied Sciences.
355	The funders had no role in study design, data collection, data analysis, data interpretation or writing
356	of the manuscript. All authors had full access to the data and had final responsibility for the decision
357	to submit the manuscript for publication.
358	
359	DATA AVAILABILITY
360	
361	Data are available upon reasonable request. All data relevant to the study are included in the article
362	or uploaded as supplementary information.

363 **REFERENCES**

364

365 1. Rampersad A, Mukundan D. Fever. Curr Opin Pediatr. 2009;21(1):139-44. doi:

366 10.1097/MOP.0b013e32832130d2.

367 2. Mukkala AN, Kwan J, Lau R, Harris D, Kain D, Boggild AK. An Update on Malaria Rapid

368 Diagnostic Tests. Curr Infect Dis Rep. 2018;20(12):49. doi: 10.1007/s11908-018-0655-4.

369 3. Oyegoke OO, Maharaj L, Akoniyon OP, Kwoji I, Roux AT, Adewumi TS, et al. Malaria

diagnostic methods with the elimination goal in view. Parasitol Res. 2022;23(1):1-19. doi:

371 10.1007/s00436-022-07512-9.

4. Wongkanya R, Pankam T, Wolf S, Pattanachaiwit S, Jantarapakde J, Pengnongyang S, et al.

373 HIV rapid diagnostic testing by lay providers in a key population-led health service programme in

374 Thailand. J Virus Erad. 2018;4(1):12-5.

375 5. Wonderly B, Jones S, Gatton ML, Barber J, Killip M, Hudson C, et al. Comparative

performance of four rapid Ebola antigen-detection lateral flow immunoassays during the 2014-2016

Ebola epidemic in West Africa. PLoS One. 2019;14(3):e0212113. doi: 10.1371/journal.pone.0212113.

378 6. Liu T, Choi G, Tang Z, Kshirsagar A, Politza AJ, Guan W. Fingerpick Blood-Based Nucleic Acid

Testing on A USB Interfaced Device towards HIV self-testing. Biosens Bioelectron. 2022;209:114255.

380 doi: 10.1016/j.bios.2022.114255.

Teggert A, Datta H, Ali Z. Biomarkers for Point-of-Care Diagnosis of Sepsis. Micromachines
 (Basel). 2020;11(3):286. doi: doi: 10.3390/mi11030286.

383 8. Anfossi L, Di Nardo F, Cavalera S, Giovannoli C, Baggiani C. Multiplex Lateral Flow

384 Immunoassay: An Overview of Strategies towards High-throughput Point-of-Need Testing.

Biosensors (Basel). 2018;9(1):2. doi: 10.3390/bios9010002.

9. Posthuma-Trumpie GA, Korf J, van Amerongen A. Lateral flow (immuno)assay: its strengths,

387 weaknesses, opportunities and threats. A literature survey. Anal Bioanal Chem. 2009;393(2):569-82.

388 doi: 10.1007/s00216-008-2287-2.

10. Chappuis F, Alirol E, d'Acremont V, Bottieau E, Yansouni CP. Rapid diagnostic tests for non-

390 malarial febrile illness in the tropics. Clin Microbiol Infect. 2013;19(5):422-31. doi: 10.1111/1469-

391 0691.12154.

392 11. Newton PN, Guerin PJ. Febrile illness mapping-much of the world without data and without

393 evidence-based treatments. BMC Med. 2018;18(1):287. doi: 10.1186/s12916-020-01747-y.

12. Chandna A, Chew R, Shwe Nwe Htun N, Peto TJ, Zhang M, Liverani M, et al. Defining the

burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of

the Rural Febrile Illness project. Wellcome Open Res. 2022;6(64). doi:

397 10.12688/wellcomeopenres.16393.2.

398 13. Dittrich S, Tadesse BT, Moussy F, Chua A, Zorzet A, Tängden T, et al. Target Product Profile

399 for a Diagnostic Assay to Differentiate between Bacterial and Non-bacterial Infections and Reduce

400 Antimicrobial Overuse in Resource-Limited Settings: An Expert Consensus. PLoS One.

401 2016;11(8):e0161721. doi: 10.1371/journal.pone.0161721.

402 14. Jacobs L, Wong HR. Emerging infection and sepsis biomarkers: will they change current

403 therapies? Expert Rev Anti Infect Ther. 2016;14:929-41. doi: 10.1080/14787210.2016.1222272.

404 15. Chandna A, Aderie EM, Ahmad R, Arguni E, Ashley EA, Cope T, et al. Prediction of disease

405 severity in young children presenting with acute febrile illness in resource-limited settings: a

406 protocol for a prospective observational study. BMJ Open. 2021;11(1):e045826. doi:

407 10.1136/bmjopen-2020-045826.

Shrestha P, Dahal P, Ogbonnaa-Njoku C, Das D, Stepniewska K, Thomas NV, et al. Nonmalarial febrile illness: a systematic review of published aetiological studies and case reports from
Southern Asia and South-eastern Asia, 1980–2015. BMC Med. 2020;18:299. doi: 10.1186/s12916020-01745-0.

Schenz J, Weigand MA, Uhle F. Molecular and biomarker-based diagnostics in early sepsis:
current challenges and future perspectives. Expert Rev Mol Diagn. 2019;19(12):1069-78. doi:
10.1080/14737159.2020.1680285.

415 18. Hopkins H, Bassat Q, Chandler CI, Crump JA, Feasey NA, Ferrand RA, et al.	I. FEDITIE IIIIIES
---	--------------------

- 416 Evaluation in a Broad Range of Endemicities (FIEBRE): protocol for a multisite prospective
- 417 observational study of the causes of fever in Africa and Asia. BMJ Open. 2020;10(7):e035632. doi:

418 10.1136/bmjopen-2019-035632.

- 419 19. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv
 420 Nurs. 2000;32(4):1008-15.
- 421 20. Varndell W, Fry M, Lutze M, D E. Use of the Delphi method to generate guidance in
- 422 emergency nursing practice: A systematic review. Int Emerg Nurs. 2021;56:100867. doi:
- 423 10.1016/j.ienj.2020.100867.
- 424 21. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining
- 425 consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. J

426 Clin Epidemiol. 2014;67:401-9. doi: 10.1016/j.jclinepi.2013.12.002.

- 427 22. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to decide its
- 428 appropriateness. World J Methodol. 2021;11(4):116-29. doi: 10.5662/wjm.v11.i4.116.
- 429 23. Yun GW, CW T. Comparative Response to a Survey Executed by Post, E-mail, & Web Form. J
- 430 Compu-Mediated Com. 2000;6(1):JCMC613. doi: 10.1111/j.1083-6101.2000.tb00112.x.
- 431 24. Boel A, Navarro-Compán V, Landewé R, van der Heijde D. Two different invitation
- 432 approaches for consecutive rounds of a Delphi survey led to comparable final outcome. J Clin
- 433 Epidemiol. 2021;129:31-9. doi: 10.1016/j.jclinepi.2020.09.034.
- 434 25. Holey EA, Feeley JL, Dixon J, Whittaker VJ. An exploration of the use of simple statistics to
- 435 measure consensus and stability in Delphi studies. BMC Med Res Methodol. 2007;7:52. doi:
- 436 10.1186/1471-2288-7-52.
- 437 26. Osborn J, Roberts T, Guillen E, Bernal O, Roddy P, Ongarello S, et al. Prioritising pathogens
 438 for the management of severe febrile patients to improve clinical care in low- and middle-income
 439 countries. BMC Infect Dis. 2020;20:117. doi: 10.1186/s12879-020-4834-1.

440 27. The Academy of Medical Sciences, National Academy of Science and Technology Philippines.

441 Improving the development and deployment of diagnostics in Southeast Asia: Workshop report.

442 London, UK: 2019.

- 443 28. Khambhati K, Bhattacharjee G, Singh V. Current progress in CRISPR-based diagnostic
- 444 platforms. J Cell Biochem. 2019;120(3):2721-5. doi: 10.1002/jcb.27690.
- 445 29. Kraemer S, Vaught JD, Bock C, Gold L, Katilius E, Keeney TR, et al. From SOMAmer-Based
- Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamline
- 447 Multiplex Proteomic Assay. PLoS One. 2011;6(10):e26332. doi: 10.1371/journal.pone.0026332.
- 448 30. Médicins San Frontières, Foundation for Innovative New Diagnostics, World Health
- 449 Organization. Target product profile (TPP) for a semi-open multiplex multi-analyte diagnostic
- 450 platform. Geneva, Switzerland: World Health Organization; 2018.

452 FIGURE LEGENDS

453

454	Figure 1. The top seven analytes, in descending order of priority based on sum of weighted scores,
455	which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for
456	acute non-malarial fever using fingerprick blood as the test substrate, in the following
457	patient populations in Mainland Southeast Asia: (A) Children presenting to primary care
458	settings (B) Adults presenting to primary care settings (C) Children being admitted to
459	secondary care settings (D) Adults being admitted to secondary care settings. Children were
460	defined as patients aged >28 days and <15 years. An analyte in rank position 1 was weighted
461	seven times more than an analyte in rank position 7; the maximum sum of weighted scores
462	per analyte was 161.
463	
464	Figure 2. The top seven analytes, in descending order of priority based on sum of weighted scores,
464 465	Figure 2. The top seven analytes, in descending order of priority based on sum of weighted scores, which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for
465	which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for
465 466	which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for acute non-malarial fever using fingerprick blood as the test substrate, in the following
465 466 467	which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for acute non-malarial fever using fingerprick blood as the test substrate, in the following patient populations in Maritime Southeast Asia: (A) Children presenting to primary care
465 466 467 468	which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for acute non-malarial fever using fingerprick blood as the test substrate, in the following patient populations in Maritime Southeast Asia: (A) Children presenting to primary care settings (B) Adults presenting to primary care settings (C) Children being admitted to
465 466 467 468 469	which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for acute non-malarial fever using fingerprick blood as the test substrate, in the following patient populations in Maritime Southeast Asia: (A) Children presenting to primary care settings (B) Adults presenting to primary care settings (C) Children being admitted to secondary care settings (D) Adults being admitted to secondary care settings. Children were
465 466 467 468 469 470	which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for acute non-malarial fever using fingerprick blood as the test substrate, in the following patient populations in Maritime Southeast Asia: (A) Children presenting to primary care settings (B) Adults presenting to primary care settings (C) Children being admitted to secondary care settings (D) Adults being admitted to secondary care settings. Children were defined as patients aged >28 days and <15 years. An analyte in rank position 1 was weighted

474 Figure 3. The top seven analytes, in descending order of priority based on sum of weighted scores,
475 which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for


476	acute non-malarial fever using fingerprick blood as the test substrate, in the following
477	patient populations in South Asia: (A) Children presenting to primary care settings (B) Adults
478	presenting to primary care settings (C) Children being admitted to secondary care settings
479	(D) Adults being admitted to secondary care settings. Children were defined as patients aged
480	>28 days and <15 years. An analyte in rank position 1 was weighted seven times more than
481	an analyte in rank position 7; the maximum sum of weighted scores per analyte was 91.

482

Figure 4. The top five commonest aetiologies of acute fever, in descending order of perceived annual
incidence based on sum of weighted scores, in the following regions: (A) Mainland Southeast
Asia (B) Maritime Southeast Asia (C) South Asia. An analyte in rank position 1 was weighted
five times more than an analyte in rank position 5; the maximum sum of weighted scores per
aetiology was 115 for Mainland Southeast Asia, 40 for Maritime Southeast Asia, and 65 for
South Asia.

489

490	Figure 5. Reasons underlying the rankings made by individual expert participants of analytes which
491	should be prioritized for inclusion in multiplex lateral flow rapid diagnostic tests for acute
492	non-malarial fever using fingerprick blood as the test substrate, in the following patient
493	populations: (A) Children presenting to primary care settings (B) Adults presenting to
494	primary care settings (C) Children being admitted to secondary care settings (D) Adults being
495	admitted to secondary care settings. Children were defined as patients aged >28 days and
496	<15 years.



| в |

Primary care: Adults




Figure 1

Α



Primary care: Children



Primary care: Adults






Figure 2



Rank position 1 Rank position 2 Rank position 3 Rank position 4 Rank position 5 Rank position 6 Rank position 7

Figure 3

Mainland Southeast Asia




Α



Streptococcus pneumoniae

Mycobacterium tuberculosis

Staphylococcus aureus



Rank position 1 Rank position 2 Rank position 3 Rank position 4 Rank position 5






Figure 5